The DOI matches its Crossref record; 212 of the 212 references it cites were found in a registry or an index.
Anticancer drug resistance: An update and perspective
Open accessAbstract
inhibitors are variable and fall into three categories, (i) new point mutations in KRas, or multiple copies of KRAS G12C which lead to higher expression level of the mutant protein; (ii) mutations in genes other than KRAS; (iii) original cancer transitioning to other cancer(s). Resistance to adagrasib, an experimental antitumor agent exerting its cytotoxic effect as a covalent inhibitor of the G12C KRas, indicated that half of the cases present multiple KRas mutations as well as allele amplification. Redundant or parallel pathways included MET amplification; emerging driver mutations in NRAS, BRAF, MAP2K1, and RET; gene fusion events in ALK, RET, BRAF, RAF1, and FGFR3; and loss-of-function mutations in NF1 and PTEN tumor suppressors. In the current review we discuss the molecular mechanisms underlying drug resistance while focusing on those emerging to common targeted cancer drivers. We also address questions of why cancers with a common driver mutation are unlikely to evolve a common drug resistance mechanism, and whether one can predict the likely mechanisms that the tumor cell may develop. These vastly important and tantalizing questions in drug discovery, and broadly in precision medicine, are the focus of our present review. We end with our perspective, which calls for target combinations to be selected and prioritized with the help of the emerging massive compute power which enables artificial intelligence, and the increased gathering of data to overcome its insatiable needs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
The Evolution and Ecology of Resistance in Cancer TherapyPreprint
Gatenby, R. A., & Brown, J. S. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a033415 · Cited by 140
RetractedPaclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
COSMIC: the Catalogue Of Somatic Mutations In Cancer
Tate, J. G., Bamford, S., Jubb, H. C., Sondka, Z., Beare, D. M., Bindal, N., Boutselakis, H., Cole, C. G., Creatore, C., Dawson, E., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1015 · Cited by 4,867
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
PubChem in 2021: new data content and improved web interfaces
Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa971 · Cited by 3,953
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Cancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
A view on drug resistance in cancer
Vasan, N., Baselga, J., & Hyman, D. M. (2019) · Nature · doi:10.1038/s41586-019-1730-1 · Cited by 2,770
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,585
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,058
RAS Proteins and Their Regulators in Human Disease
Simanshu, D. K., Nissley, D. V., & McCormick, F. (2017) · Cell · doi:10.1016/j.cell.2017.06.009 · Cited by 1,943
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., Griffin, J. D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025217 · Cited by 1,718
KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
Pao, W., Wang, T. Y., Riely, G. J., Miller, V. A., Pan, Q., Ladanyi, M., Zakowski, M. F., Heelan, R. T., Kris, M. G., & Varmus, H. E. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020017 · Cited by 1,516
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Somatic mutation in cancer and normal cells
Martincorena, I., & Campbell, P. J. (2015) · Science · doi:10.1126/science.aab4082 · Cited by 1,396
Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma
Johnson, B. E., Mazor, T., Hong, C., Barnes, M., Aihara, K., McLean, C. Y., Fouse, S. D., Yamamoto, S., Ueda, H., Tatsuno, K., et al. (2014) · Science · doi:10.1126/science.1239947 · Cited by 1,362
Epigenetic plasticity and the hallmarks of cancer
Flavahan, W. A., Gaskell, E., & Bernstein, B. E. (2017) · Science · doi:10.1126/science.aal2380 · Cited by 1,340
The updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
Cancer Genetics and Epigenetics: Two Sides of the Same Coin?
You, J. S., & Jones, P. A. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.008 · Cited by 1,167
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Wilson, T. R., Fridlyand, J., Yan, Y., Penuel, E., Burton, L., Chan, E., Peng, J., Lin, E., Wang, Y., Sosman, J., et al. (2012) · Nature · doi:10.1038/nature11249 · Cited by 1,134
The Frequency of Ras Mutations in Cancer
Prior, I. A., Hood, F. E., & Hartley, J. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3682 · Cited by 1,130
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
The evolutionary history of 2,658 cancers
Gerstung, M., Jolly, C., Leshchiner, I., Dentro, S. C., Gonzalez, S., Rosebrock, D., Mitchell, T. J., Rubanova, Y., Anur, P., Yu, K., et al. (2020) · Nature · doi:10.1038/s41586-019-1907-7 · Cited by 1,057
O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Hata, A. N., Niederst, M. J., Archibald, H. L., Gomez-Caraballo, M., Siddiqui, F. M., Mulvey, H. E., Maruvka, Y. E., Ji, F., Bhang, H.-E. C., Krishnamurthy Radhakrishna, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4040 · Cited by 985
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973
Oser, M. G., Niederst, M. J., Sequist, L. V., & Engelman, J. A. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71180-5 · Cited by 942
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938
Cancer Epigenetics: Tumor Heterogeneity, Plasticity of Stem-like States, and Drug Resistance
Easwaran, H., Tsai, H.-C., & Baylin, S. B. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.05.015 · Cited by 915
Epigenetic modulators, modifiers and mediators in cancer aetiology and progression
Feinberg, A. P., Koldobskiy, M. A., & Göndör, A. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2016.13 · Cited by 841
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
Epigenetic reprogramming in cancer
Suvà, M. L., Riggi, N., & Bernstein, B. E. (2013) · Science · doi:10.1126/science.1230184 · Cited by 706
Targeting the cancer kinome through polypharmacology
Knight, Z. A., Lin, H., & Shokat, K. M. (2010) · Nature reviews. Cancer · doi:10.1038/nrc2787 · Cited by 674
Li, W., Zhang, H., Assaraf, Y. G., Zhao, K., Xu, X., Xie, J., Yang, D.-H., & Chen, Z.-S. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.05.001 · Cited by 673
Lim, Z.-F., & Ma, P. C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0818-2 · Cited by 630
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1
Wylie, A. A., Schoepfer, J., Jahnke, W., Cowan-Jacob, S. W., Loo, A., Furet, P., Marzinzik, A. L., Pelle, X., Donovan, J., Zhu, W., et al. (2017) · Nature · doi:10.1038/nature21702 · Cited by 614
Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules.
Gibbs, J. B., Sigal, I. S., Poe, M., & Scolnick, E. M. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.18.5704 · Cited by 609
Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors
Zhang, J., Adrián, F. J., Jahnke, W., Cowan-Jacob, S. W., Li, A. G., Iacob, R. E., Sim, T., Powers, J., Dierks, C., Sun, F., et al. (2010) · Nature · doi:10.1038/nature08675 · Cited by 597
Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment
Wojtkowiak, J. W., Verduzco, D., Schramm, K. J., & Gillies, R. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200292c · Cited by 566
The multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528
Timing the Landmark Events in the Evolution of Clear Cell Renal Cell Cancer: TRACERx Renal
Mitchell, T. J., Turajlic, S., Rowan, A., Nicol, D., Farmery, J. H. R., O’Brien, T., Martincorena, I., Tarpey, P., Angelopoulos, N., Yates, L. R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.020 · Cited by 513
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507
Circumventing cancer drug resistance in the era of personalized medicine
Garraway, L. A., & Jänne, P. A. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0012 · Cited by 503
Zhu, C., Wei, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1090-3 · Cited by 488
Lysosomes as mediators of drug resistance in cancer
Zhitomirsky, B., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.004 · Cited by 482
Cancer epigenetics: Moving forward
Nebbioso, A., Tambaro, F. P., Dell’Aversana, C., & Altucci, L. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007362 · Cited by 480
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1
Schoepfer, J., Jahnke, W., Berellini, G., Buonamici, S., Cotesta, S., Cowan-Jacob, S. W., Dodd, S., Drueckes, P., Fabbro, D., Gabriel, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01040 · Cited by 454
PI3K signaling in cancer: beyond AKT
Lien, E. C., Dibble, C. C., & Toker, A. (2017) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2017.02.007 · Cited by 451
Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
Gonen, N., & Assaraf, Y. G. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.07.002 · Cited by 437
Only three driver gene mutations are required for the development of lung and colorectal cancers
Tomasetti, C., Marchionni, L., Nowak, M. A., Parmigiani, G., & Vogelstein, B. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1421839112 · Cited by 395
Allosteric inhibitors of Bcr-abl–dependent cell proliferation
Adrián, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio760 · Cited by 381
KRAS Alleles: The Devil Is in the Detail
Haigis, K. M. (2017) · Trends in Cancer · doi:10.1016/j.trecan.2017.08.006 · Cited by 373
AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
Taniguchi, H., Yamada, T., Wang, R., Tanimura, K., Adachi, Y., Nishiyama, A., Tanimoto, A., Takeuchi, S., Araujo, L. H., Boroni, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08074-0 · Cited by 356
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355
Self-citationDriver and Passenger Mutations in Cancer
Pon, J. R., & Marra, M. A. (2015) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012414-040312 · Cited by 355
Chen, L. L., Trent, J. C., Wu, E. F., Fuller, G. N., Ramdas, L., Zhang, W., Raymond, A. K., Prieto, V. G., Oyedeji, C. O., Hunt, K. K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0085 · Cited by 339
Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance
Narayanan, S., Cai, C.-Y., Assaraf, Y. G., Guo, H.-Q., Cui, Q., Wei, L., Huang, J.-J., Ashby, C. R., & Chen, Z.-S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100663 · Cited by 332
Molecular chess? Hallmarks of anti-cancer drug resistance
Cree, I. A., & Charlton, P. (2017) · BMC Cancer · doi:10.1186/s12885-016-2999-1 · Cited by 325
Tamborini, E., Bonadiman, L., Greco, A., Albertini, V., Negri, T., Gronchi, A., Bertulli, R., Colecchia, M., Casali, P. G., Pierotti, M. A., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.02.021 · Cited by 324
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
The role of alternative splicing in cancer: From oncogenesis to drug resistance
Sciarrillo, R., Wojtuszkiewicz, A., Assaraf, Y. G., Jansen, G., Kaspers, G. J. L., Giovannetti, E., & Cloos, J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100728 · Cited by 307
Papa, A., & Pandolfi, P. P. (2019) · Biomolecules · doi:10.3390/biom9040153 · Cited by 303
Rubio-Perez, C., Tamborero, D., Schroeder, M. P., Antolín, A. A., Deu-Pons, J., Perez-Llamas, C., Mestres, J., Gonzalez-Perez, A., & Lopez-Bigas, N. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.007 · Cited by 296
Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer
Akdemir, K. C., Le, V. T., Chandran, S., Li, Y., Verhaak, R. G., Beroukhim, R., Campbell, P. J., Chin, L., Dixon, J. R., Futreal, P. A., et al. (2020) · Nature Genetics · doi:10.1038/s41588-019-0564-y · Cited by 283
Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
Vasan, N., Razavi, P., Johnson, J. L., Shao, H., Shah, H., Antoine, A., Ladewig, E., Gorelick, A., Lin, T.-Y., Toska, E., et al. (2019) · Science · doi:10.1126/science.aaw9032 · Cited by 283
Drug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
Aissa, A. F., Islam, A. B. M. M. K., Ariss, M. M., Go, C. C., Rader, A. E., Conrardy, R. D., Gajda, A. M., Rubio-Perez, C., Valyi-Nagy, K., Pasquinelli, M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21884-z · Cited by 273
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272
Taylor, S., Spugnini, E. P., Assaraf, Y. G., Azzarito, T., Rauch, C., & Fais, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.004 · Cited by 259
NMR-based functional profiling of RASopathies and oncogenic RAS mutations
Smith, M. J., Neel, B. G., & Ikura, M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218173110 · Cited by 257
A Comparative Analysis of Individual RAS Mutations in Cancer Biology
Muñoz-Maldonado, C., Zimmer, Y., & Medová, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01088 · Cited by 254
The effects of chromatin organization on variation in mutation rates in the genome
Makova, K. D., & Hardison, R. C. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3890 · Cited by 253
Therapeutic strategies to overcome taxane resistance in cancer
Das, T., Anand, U., Pandey, S. K., Ashby, C. R., Assaraf, Y. G., Chen, Z.-S., & Dey, A. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100754 · Cited by 253
Eide, C. A., Zabriskie, M. S., Savage Stevens, S. L., Antelope, O., Vellore, N. A., Than, H., Schultz, A. R., Clair, P., Bowler, A. D., Pomicter, A. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.004 · Cited by 247
Targeting Epigenetics in Cancer
Bennett, R. L., & Licht, J. D. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-105106 · Cited by 246
Wnt Signaling and Drug Resistance in Cancer
Zhong, Z., & Virshup, D. M. (2020) · Molecular Pharmacology · doi:10.1124/mol.119.117978 · Cited by 241
Wang, J.-Q., Yang, Y., Cai, C.-Y., Teng, Q.-X., Cui, Q., Lin, J., Assaraf, Y. G., & Chen, Z.-S. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100743 · Cited by 241
Comprehensive characterization of protein–protein interactions perturbed by disease mutations
Cheng, F., Zhao, J., Wang, Y., Lu, W., Liu, Z., Zhou, Y., Martin, W. R., Wang, R., Huang, J., Hao, T., et al. (2021) · Nature Genetics · doi:10.1038/s41588-020-00774-y · Cited by 227
K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
Tsai, F. D., Lopes, M. S., Zhou, M., Court, H., Ponce, O., Fiordalisi, J. J., Gierut, J. J., Cox, A. D., Haigis, K. M., & Philips, M. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412811112 · Cited by 226
Zhitomirsky, B., & Assaraf, Y. G. (2015) · Oncotarget · doi:10.18632/oncotarget.2732 · Cited by 225
Mutation-Specific RAS Oncogenicity Explains NRAS Codon 61 Selection in Melanoma
Burd, C. E., Liu, W., Huynh, M. V., Waqas, M. A., Gillahan, J. E., Clark, K. S., Fu, K., Martin, B. L., Jeck, W. R., Souroullas, G. P., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0729 · Cited by 216
Serebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11530-0 · Cited by 215
Kohsaka, S., Nagano, M., Ueno, T., Suehara, Y., Hayashi, T., Shimada, N., Takahashi, K., Suzuki, K., Takamochi, K., Takahashi, F., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan6566 · Cited by 210
Epigenetic mechanisms as a new approach in cancer treatment: An updated review
Fardi, M., Solali, S., & Farshdousti Hagh, M. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.06.003 · Cited by 209
An analysis of genetic heterogeneity in untreated cancers
Reiter, J. G., Baretti, M., Gerold, J. M., Makohon-Moore, A. P., Daud, A., Iacobuzio-Donahue, C. A., Azad, N. S., Kinzler, K. W., Nowak, M. A., & Vogelstein, B. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0185-x · Cited by 209
KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma
Bournet, B., Muscari, F., Buscail, C., Assenat, E., Barthet, M., Hammel, P., Selves, J., Guimbaud, R., Cordelier, P., & Buscail, L. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.18 · Cited by 205
Tissue-Specific Oncogenic Activity of KRASA146T
Poulin, E. J., Bera, A. K., Lu, J., Lin, Y.-J., Strasser, S. D., Paulo, J. A., Huang, T. Q., Morales, C., Yan, W., Cook, J., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1220 · Cited by 197
Sabnis, A. J., & Bivona, T. G. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.12.009 · Cited by 189
Li, B., Jiang, J., Assaraf, Y. G., Xiao, H., Chen, Z.-S., & Huang, C. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100720 · Cited by 188
Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
Wijdeven, R. H., Pang, B., Assaraf, Y. G., & Neefjes, J. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.07.001 · Cited by 187
Gremke, N., Polo, P., Dort, A., Schneikert, J., Elmshäuser, S., Brehm, C., Klingmüller, U., Schmitt, A., Reinhardt, H. C., Timofeev, O., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18504-7 · Cited by 187
Novel nanomedicines to overcome cancer multidrug resistance
Su, Z., Dong, S., Zhao, S.-C., Liu, K., Tan, Y., Jiang, X., Assaraf, Y. G., Qin, B., Chen, Z.-S., & Zou, C. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100777 · Cited by 182
PI3K inhibitors: review and new strategies
Zhang, M., Jang, H., & Nussinov, R. (2020) · Chemical Science · doi:10.1039/d0sc01676d · Cited by 178
Self-citationMechanisms of acquired tumor drug resistance
Aleksakhina, S. N., Kashyap, A., & Imyanitov, E. N. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.188310 · Cited by 177
Pontiggia, O., Sampayo, R., Raffo, D., Motter, A., Xu, R., Bissell, M. J., de Kier Joffé, E. B., & Simian, M. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1766-x · Cited by 166
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance
Shahar, N., & Larisch, S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100712 · Cited by 165
Rare Codons Regulate KRas Oncogenesis
Lampson, B. L., Pershing, N. L., Prinz, J. A., Lacsina, J. R., Marzluff, W. F., Nicchitta, C. V., MacAlpine, D. M., & Counter, C. M. (2012) · Current Biology · doi:10.1016/j.cub.2012.11.031 · Cited by 164
Genovese, I., Ilari, A., Assaraf, Y. G., Fazi, F., & Colotti, G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.10.003 · Cited by 156
The emergence of drug resistance to targeted cancer therapies: Clinical evidence
Sarmento‐Ribeiro, A. B., Scorilas, A., Gonçalves, A. C., Efferth, T., & Trougakos, I. P. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100646 · Cited by 149
Induction of a Timed Metabolic Collapse to Overcome Cancer Chemoresistance
van Gastel, N., Spinelli, J. B., Sharda, A., Schajnovitz, A., Baryawno, N., Rhee, C., Oki, T., Grace, E., Soled, H. J., Milosevic, J., et al. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.07.009 · Cited by 148
Nussinov, R., Jang, H., Tsai, C., & Cheng, F. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006658 · Cited by 146
Self-citationLandscape and function of multiple mutations within individual oncogenes
Saito, Y., Koya, J., Araki, M., Kogure, Y., Shingaki, S., Tabata, M., McClure, M. B., Yoshifuji, K., Matsumoto, S., Isaka, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2175-2 · Cited by 144
Cancer cell adaptation to chemotherapy
Nicolantonio, F. D., Mercer, S. J., Knight, L. A., Gabriel, F. G., Whitehouse, P. A., Sharma, S., Fernando, A., Glaysher, S., Palma, S. D., Johnson, P., et al. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-78 · Cited by 139
Jiang, W., Xia, J., Xie, S., Zou, R., Pan, S., Wang, Z. P., Assaraf, Y. G., & Zhu, X. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100683 · Cited by 132
Mechanisms of Resistance to KRASG12C Inhibitors
Dunnett-Kane, V., Nicola, P. A., Blackhall, F. H., & Lindsay, C. R. (2021) · Cancers · doi:10.3390/cancers13010151 · Cited by 131
Arruabarrena-Aristorena, A., Maag, J. L. V., Kittane, S., Cai, Y., Karthaus, W. R., Ladewig, E., Park, J., Kannan, S., Ferrando, L., Cocco, E., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.003 · Cited by 130
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function
Gao, L., Wu, Z., Assaraf, Y. G., Chen, Z., & Wang, L. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100770 · Cited by 129
Oncogenic Ras Isoforms Signaling Specificity at the Membrane
Nussinov, R., Tsai, C., & Jang, H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2727 · Cited by 126
Self-citationSomatic mutation distributions in cancer genomes vary with three-dimensional chromatin structure
Akdemir, K. C., Le, V. T., Kim, J. M., Killcoyne, S., King, D. A., Lin, Y., Tian, Y., Inoue, A., Amin, S. B., Robinson, F. S., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0708-0 · Cited by 122
Unraveling structural mechanisms of allosteric drug action
Nussinov, R., & Tsai, C.-J. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.03.006 · Cited by 119
Self-citationOgura, T., Yamao, K., Hara, K., Mizuno, N., Hijioka, S., Imaoka, H., Sawaki, A., Niwa, Y., Tajika, M., Kondo, S., et al. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0664-2 · Cited by 118
Epigenomic regulation of oncogenesis by chromatin remodeling
Kumar, R., Li, D.-Q., Müller, S., & Knapp, S. (2016) · Oncogene · doi:10.1038/onc.2015.513 · Cited by 117
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer
Chiappa, M., Guffanti, F., Bertoni, F., Colombo, I., & Damia, G. L. M. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100744 · Cited by 116
Harbinski, F., Craig, V. J., Sanghavi, S., Jeffery, D. A., Liu, L., Sheppard, K. A., Wagner, S., Stamm, C., Buneß, A., Chatenay‐Rivauday, C., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0237 · Cited by 114
Overcoming apoptosis deficiency of melanoma—Hope for new therapeutic approaches
Eberle, J., Kurbanov, B. M., Hossini, A. M., Trefzer, U., & Fecker, L. F. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.09.001 · Cited by 113
Novel Extracellular Vesicles Mediate an ABCG2-Dependent Anticancer Drug Sequestration and Resistance
Ifergan, I., Scheffer, G. L., & Assaraf, Y. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2021 · Cited by 110
Blons, H., Emile, J. F., Le Malicot, K., Julié, C., Zaanan, A., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J. L., Thaler, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu464 · Cited by 108
Kim, D., Bach, D., Fan, Y., Luu, T.-T.-T., Hong, J., Park, H. J., & Lee, S. K. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1601-6 · Cited by 103
Prediction of Cancer Drug Resistance and Implications for Personalized Medicine
Volm, M., & Efferth, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00282 · Cited by 102
van der Wekken, A. J., Saber, A., Hiltermann, T. J. N., Kok, K., van den -->Berg, A., & Groen, H. J. M. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.01.024 · Cited by 102
Finding driver mutations in cancer: Elucidating the role of background mutational processes
Brown, A., Li, M., Goncearenco, A., & Panchenko, A. R. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006981 · Cited by 102
A New View of Pathway-Driven Drug Resistance in Tumor Proliferation
Nussinov, R., Tsai, C., & Jang, H. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.02.001 · Cited by 101
Self-citationResistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma
Neel, D. S., & Bivona, T. G. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0007-0 · Cited by 98
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer
Pecoraro, C., Faggion, B., Balboni, B., Carbone, D., Peters, G. J., Diana, P., Assaraf, Y. G., & Giovannetti, E. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100779 · Cited by 96
‘Latent drivers’ expand the cancer mutational landscape
Nussinov, R., & Tsai, C. (2015) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2015.01.004 · Cited by 94
Self-citationCross-resistance and drug sequence in prostate cancer
Buck, S. A. J., Koolen, S. L. W., Mathijssen, R. H. J., de Wit, R., & van Soest, R. J. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100761 · Cited by 88
Emerging roles of F-box proteins in cancer drug resistance
Yan, L., Lin, M., Pan, S., Assaraf, Y. G., Wang, Z. P., & Zhu, X. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100673 · Cited by 85
Goler-Baron, V., Sladkevich, I., & Assaraf, Y. G. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.033 · Cited by 83
Nicolini, F. E., Ibrahim, A. R., Soverini, S., Martinelli, G., Müller, M. C., Hochhaus, A., Dufva, I. H., Kim, D.-W., Cortes, J. E., Mauro, M. J., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.080234 · Cited by 81
Mutational analysis and clinical correlation of metastatic colorectal cancer
Russo, A. L., Borger, D. R., Szymonifka, J. D., Ryan, D. P., Wo, J. Y.-L., Blaszkowsky, L. S., Kwak, E. L., Allen, J. N., Wadlow, R. C., Zhu, A. X., et al. (2014) · Cancer · doi:10.1002/cncr.28599 · Cited by 77
Drug resistance in cancer: molecular evolution and compensatory proliferation
Friedman, R. (2016) · Oncotarget · doi:10.18632/oncotarget.7459 · Cited by 77
Advanced technological tools to study multidrug resistance in cancer
Andrei, L., Kasas, S., Ochoa, I., Stanković, T., Korsnes, M. S., Václavíková, R., Assaraf, Y. G., & Pešić, M. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100658 · Cited by 74
Jiang, T., Chen, X., Ren, X., Yang, J., & Cheng, Y. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100752 · Cited by 73
Xu, J., Haigis, K. M., Firestone, A. J., McNerney, M. E., Li, Q., Davis, E., Chen, S.-C., Nakitandwe, J., Downing, J. R., Jacks, T., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0096 · Cited by 71
Monica, S. L., Minari, R., Cretella, D., Flammini, L., Fumarola, C., Bonelli, M. A., Cavazzoni, A., Digiacomo, G., Galetti, M., Madeddu, D., et al. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1240-x · Cited by 71
Extensive subclonal mutational diversity in human colorectal cancer and its significance
Loeb, L. A., Kohrn, B. F., Loubet-Senear, K. J., Dunn, Y. J., Ahn, E. H., O'Sullivan, J. N., Salk, J. J., Bronner, M. P., & Beckman, R. A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910301116 · Cited by 71
Oncogenic PIK3CA promotes cellular stemness in an allele dose-dependent manner
Madsen, R. R., Knox, R. G., Pearce, W. P., López, S., Mahler-Araujo, B. M., McGranahan, N., Vanhaesebroeck, B., & Semple, R. K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1821093116 · Cited by 69
The mechanism of full activation of tumor suppressor PTEN at the phosphoinositide-enriched membrane
Jang, H., Smith, I. N., Eng, C., & Nussinov, R. (2021) · iScience · doi:10.1016/j.isci.2021.102438 · Cited by 66
Self-citationStarvation, detoxification, and multidrug resistance in cancer therapy
Lee, C. D., Raffaghello, L., & Longo, V. D. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.004 · Cited by 63
Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health
Cheng, F., Liang, H., Butte, A. J., Eng, C., & Nussinov, R. (2018) · Pharmacological Reviews · doi:10.1124/pr.118.016253 · Cited by 61
Self-citationA Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer
Ruan, T., Liu, W., Tao, K., & Wu, C. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s239336 · Cited by 60
The role of endolysosomal trafficking in anticancer drug resistance
Hussein, N. A., Malla, S., Pasternak, M. A., Terrero, D., Brown, N. G., Ashby, C. R., Assaraf, Y. G., Chen, Z., & Tiwari, A. K. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100769 · Cited by 60
Comprehensive assessment of computational algorithms in predicting cancer driver mutations
Chen, H., Li, J., Wang, Y., Ng, P. K., Tsang, Y. H., Shaw, K. R. M., Mills, G. B., & Liang, H. (2020) · Genome biology · doi:10.1186/s13059-020-01954-z · Cited by 59
Lantermann, A. B., Chen, D., McCutcheon, K., Hoffman, G., Frias, E., Ruddy, D. A., Rakiec, D. P., Korn, J. M., McAllister, G., Stegmeier, F. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1113 · Cited by 58
Saleem, H., Abdul, U. K., Küçükosmanoğlu, A., Houweling, M., Cornelissen, F. M. G., Heiland, D. H., Hegi, M. E., Kouwenhoven, M. C. M., Bailey, D. S., Würdinger, T., et al. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.04.002 · Cited by 57
Rolfo, C. D., Fanale, D., Hong, D. S., Tsimberidou, A. M., Piha-Paul, S. A., Pauwels, P., van Meerbeeck, J. P., Caruso, S., Bazan, V., Cicero, G., et al. (2014) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201015666140519123219 · Cited by 56
Genotype and phenotype spectrum of NRAS germline variants
Altmüller, F., Lißewski, C., Bertola, D. R., Flex, E., Stark, Z., Spranger, S., Baynam, G. S., Buscarilli, M., Dyack, S., Gillis, J., et al. (2017) · European Journal of Human Genetics · doi:10.1038/ejhg.2017.65 · Cited by 56
Precision medicine review: rare driver mutations and their biophysical classification
Nussinov, R., Jang, H., Tsai, C., & Cheng, F. (2019) · Biophysical Reviews · doi:10.1007/s12551-018-0496-2 · Cited by 56
Self-citationKaemmerer, E., Loessner, D., & Avery, V. M. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.11.030 · Cited by 56
A new precision medicine initiative at the dawn of exascale computing
Nussinov, R., Jang, H., Nir, G., Tsai, C., & Cheng, F. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00420-3 · Cited by 55
Self-citationThe structural basis for cancer treatment decisions
Nussinov, R., Jang, H., & Tsai, C. (2014) · Oncotarget · doi:10.18632/oncotarget.2439 · Cited by 54
Self-citationPrieto‐Vila, M., Usuba, W., Takahashi, R., Shimomura, I., Sasaki, H., Ochiya, T., & Yamamoto, Y. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0122 · Cited by 54
Why Are Some Driver Mutations Rare?
Nussinov, R., Tsai, C., & Jang, H. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.10.003 · Cited by 51
Self-citationLiu, C., Zhao, J., Lü, W., Dai, Y., Hockings, J. K., Zhou, Y., Nussinov, R., Eng, C., & Cheng, F. (2020) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007701 · Cited by 51
Self-citationLong, L., Assaraf, Y. G., Lei, Z., Peng, H., Yang, L., Chen, Z., & Ren, S. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100703 · Cited by 50
Tourneau, C. L., Servois, V., Dieras, V. C., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.10 · Cited by 46
Ras and Ras mutations in cancer
Rajasekharan, S., & Raman, T. (2013) · Open Life Sciences · doi:10.2478/s11535-013-0158-5 · Cited by 46
Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels
Du, J., Gu, J., & Li, J. (2020) · Bioscience Reports · doi:10.1042/bsr20200401 · Cited by 46
Levin, M., Stark, M., Ofran, Y., & Assaraf, Y. G. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01746-w · Cited by 45
Group Behavior and Emergence of Cancer Drug Resistance
Bhattacharya, S., Mohanty, A. R., Achuthan, S., Kotnala, S., Jolly, M. K., Kulkarni, P., & Salgia, R. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.01.009 · Cited by 45
Assaraf, Y. G., Molina, A., & SCHIMKE, R. T. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)51467-8 · Cited by 43
PI3K Driver Mutations: A Biophysical Membrane-Centric Perspective
Zhang, M., Jang, H., & Nussinov, R. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0911 · Cited by 43
Self-citationBram, E. E., Ifergan, I., Grimberg, M., Lemke, K., Składanowski, A., & Assaraf, Y. G. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.03.028 · Cited by 41
Glaysher, S., Yiannakis, D., Gabriel, F. G., Johnson, P., Polak, M. E., Knight, L. A., Goldthorpe, Z., Peregrin, K., Gyi, M. M., Modi, P., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-300 · Cited by 41
Schmitt, M. W., Pritchard, J. R., Leighow, S. M., Aminov, B. I., Beppu, L. W., Kim, D. S., Hodgson, J., Rivera, V. M., Loeb, L. A., & Radich, J. P. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0167 · Cited by 39
Nussinov, R., Jang, H., Tsai, C., & Cheng, F. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007114 · Cited by 39
Self-citationCrudden, C., Ilic, M., Suleymanova, N., Worrall, C., Girnita, A., & Girnita, L. (2014) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2014.10.002 · Cited by 37
Autoinhibition can identify rare driver mutations and advise pharmacology
Nussinov, R., Tsai, C., & Jang, H. (2019) · The FASEB Journal · doi:10.1096/fj.201901341r · Cited by 35
Self-citationSeton-Rogers, S. E. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0228-3 · Cited by 34
The pharmacogenomics of drug resistance to protein kinase inhibitors
Gillis, N., & McLeod, H. L. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.008 · Cited by 33
Are Parallel Proliferation Pathways Redundant?
Nussinov, R., Tsai, C., & Jang, H. (2020) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2020.03.013 · Cited by 33
Self-citationTwo novel germline KRAS mutations: expanding the molecular and clinical phenotype
Stark, Z., Gillessen‐Kaesbach, G., Ryan, M. M., Cirstea, I. C., Gremer, L., Ahmadian, M., Savarirayan, R., & Zenker, M. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01754.x · Cited by 31
Structural basis of the atypical activation mechanism of KRASV14I
Bera, A. K., Lu, J., Wales, T. E., Gondi, S. R., Gurbani, D., Nelson, A., Engen, J. R., & Westover, K. D. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009131 · Cited by 31
Ras isoform-specific expression, chromatin accessibility, and signaling
Nussinov, R., Zhang, M., Maloney, R., & Jang, H. (2021) · Biophysical Reviews · doi:10.1007/s12551-021-00817-6 · Cited by 29
Self-citationStephens, R. M., Yi, M., Kessing, B. D., Nissley, D. V., & McCormick, F. P. (2017) · Cancer Informatics · doi:10.1177/1176935117711944 · Cited by 26
Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns
Mateo, L., Duran‐Frigola, M., Gris‐Oliver, A., Palafox, M., Scaltriti, M., Razavi, P., Chandarlapaty, S., Arribas, J., Bellet, M., Serra, V., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00774-x · Cited by 25
Roots of imatinib resistance: A question of self-renewal?
Burchert, A. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.06.001 · Cited by 24
Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy
Glaysher, S., Gabriel, F. G., Johnson, P., Polak, M. E., Knight, L. A., Parker, K., Poole, M., Narayanan, A., & Cree, I. A. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605817 · Cited by 24
Tamai, M., Inukai, T., Kojika, S., Abe, M., Kagami, K., Harama, D., Shinohara, T., Watanabe, A., Oshiro, H., Akahane, K., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27767-6 · Cited by 24
The cell biology behind the oncogenic PIP3 lipids
Carrera, A. C., & Anderson, R. (2019) · Journal of Cell Science · doi:10.1242/jcs.228395 · Cited by 23
Cited by
Unveiling the mechanisms and challenges of cancer drug resistance
Khan, S. U., Fatima, K., Aisha, S., & Malik, F. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01302-1 · Cited by 417
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Nussinov, R., Zhang, M., Maloney, R., Liu, Y., Tsai, C.-J., & Jang, H. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167569 · Cited by 66
Self-citationLiu, Y., Zhang, W., Jang, H., & Nussinov, R. (2025) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c02022 · Cited by 10
Self-citation
Metadata
- Authors
- Nussinov, R., Tsai, C.-J., & Jang, H.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 59
- Pages
- 100796
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W4200191138
- Cited by
- 386
- References
- 212
- FWCI
- 32.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.